NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...
Stocktwits on MSN
Pfizer CEO eyes big push towards obesity drug development in 2026 after $10B Metsera acquisition
Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The company purchased Metsera in November for up to $10 billion to reignite its ...
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...
Considerable on MSN
Pfizer channels COVID windfall into cancer
Pfizer is steering much of its pandemic revenue into oncology, as Chief Executive Albert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results